FDA Grants Orphan Drug Status to Ariceum’s SSTR2-Targeting SCLC Therapy
A new cancer treatment just received special recognition from the FDA, marking an important step forward for patients with an aggressive type of lung cancer. The treatment, developed by Ariceum Therapeutics, targets